• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Economy

OPK Stock Price, Analysis and Forecast: Should You Invest

by September 12, 2024
written by September 12, 2024

Should You Invest in OPK Stock?

OPKO Health, one of the leading pharmaceutical companies, is a key player in the market. If you’re considering investing in the health and pharmaceutical sector, particularly in OPK stock, keep reading to find out more.

OPKO Health shareholders have experienced a 36% decline over the past year, while the broader market has risen 25%. The stock will find some support from the long-term average at approximately $1.51 on a fall. A break-up through the short-term average will send a buy signal. Let’ see in detail OPK stock price analysis and forecasts. 

OPK Stock Price Today

Opko Health, Inc. (OPK) is a healthcare company trading at $1.59 per share. Over the past 52 weeks, the stock has fluctuated between a low of $0.85 and a high of $1.76. The company has a market capitalisation of $1.1 billion, classifying it as a small-cap stock. Opko Health does not pay any dividends, which might affect income-seeking investors. The stock has a beta of 1.64, indicating it is more volatile than the broader market.

Investors looking to buy OPKO stock should consider its current price stability and market volatility. The stock’s lack of dividends may deter those seeking regular income. However, its relatively low price could attract those seeking growth in the healthcare sector.

Before investing, it is essential to understand the company’s fundamentals and market position. Opko Health operates in a competitive healthcare environment, and its stock performance reflects this.

The company may offer an opportunity for growth-focused investors, but its volatility and lack of dividends should be considered. Researching thoroughly and assessing personal financial goals before deciding to invest is important.

OPK Stock Forecast: New Price Targets

OPK stock news has received various research ratings. Barrington Research increased its price target from $1.50 to $2.25, rating the stock “outperform.” HC Wainwright reissued a “buy” rating with a $3.00 target price. Piper Sandler lowered its target from $5.00 to $3.00 and rated it “overweight.”

OPKO Health has a market cap of $1.12 billion, a negative P/E ratio of -4.57, and a beta of 1.65. Its quarterly earnings beat expectations, reporting a loss of $0.01 per share versus an expected loss of $0.09. Revenue fell 31.3% year over year to $182.20 million. Analysts predict OPKO will post a -0.29 EPS for the year.

Insider Activity at OPKO Health

OPKO Health’s major shareholder sold 12,994 shares on August 6th at $29.35 per share, totalling $381,373.90. After the sale, the shareholder holds 2,971,570 shares, valued at $87,215,579.50. Over the last 90 days, insiders sold 736,644 shares worth $23,874,134. Insiders currently own 47.26% of the company’s stock.

Recent insider sales at OPKO Health indicate potential caution among major shareholders despite their significant remaining ownership stake.

OPKO Health: Different Segments

The company has multiple branches that research and deal with different fields. For example, the Diagnostics segment includes BioReference Laboratories, leading clinical laboratories offering comprehensive healthcare testing solutions. Meanwhile, the Pharmaceuticals segment encompasses speciality pharmaceuticals, such as Rayaldee, used to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease, and VARUBI, which addresses chemotherapy-induced nausea and vomiting. In addition, OPKO Health is developing a potential cure for type 1 diabetes and enhancing patient outcomes through strategic partnerships and innovative solutions.

Final Thoughts: OPK Stock, Buy or Sell?

The OPKO Health stock provides both opportunities and risks for investors. Its current low price and long-term potential in the healthcare and pharmaceutical sectors may attract growth-focused investors, particularly given the company’s work on innovative treatments like a potential cure for type 1 diabetes. However, the stock’s volatility, lack of dividends, and recent insider sales suggest caution. Investors should consider their risk tolerance and long-term goals before investing in OPKO Health.

The post OPK Stock Price, Analysis and Forecast: Should You Invest appeared first on FinanceBrokerage.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Majority of Americans don’t trust AI-generated election information, poll finds
next post
Solana and Cardano: Cardano at new monthly high

related articles

Trump’s Fed Criticism Sparks Investor Concerns

April 22, 2025

Oil Prices Rebound After Trump’s Criticism of Powell

April 22, 2025

Buy Bitcoin Under $100K Before The Next Bull...

April 22, 2025

BNB Price Surge Leads Crypto Gains as Bitcoin...

April 21, 2025

Fed’s Stagflation Warning Impacts Crypto Markets

April 21, 2025

Bitcoin Slips to $83.6K Amid Nvidia’s $5.5B Charge

April 21, 2025

Gold Price Surge Hits $3,385 Amid Trade Tensions

April 21, 2025

Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

April 21, 2025

Memecoins, AI, and DeFi Tokens Lead Crypto Rebound

April 21, 2025

Bitcoin Nears $85K Amid Market Optimism

April 21, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Dogecoin is under pressure from the weekly resistance zone

    August 8, 2024
  • Balance of power: Jockeying begins for House Freedom Caucus top spot after leader’s unprecedented primary loss

    August 4, 2024
  • Bitcoin Price UK May Surge If Britain Sells Their £4B Stash

    July 23, 2024
  • Long US30: primed for Rebound, strong support at 38,550 and positive labor data fuel optimism

    August 8, 2024
  • American Marc Fogel released from Russian custody

    February 11, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,735)
  • Investing (624)
  • Stock (775)

Latest Posts

  • Biden exiting race but serving out term would leave Harris in dilemma: expert

    July 10, 2024
  • Ripple and Tron: Tron is once again close to the weekly high

    July 25, 2024
  • Special Counsel Smith seeks to dismiss Jan. 6 charges, appeal in classified records case against Trump

    November 25, 2024

Recent Posts

  • SafeMoon and Litecoin: Litecoin at the door of a new high

    September 4, 2024
  • Biden jokes about impending exit from the White House: ‘Looking for a job’

    August 14, 2024
  • CFPB expands oversight of digital payments services including Apple Pay and Cash App

    November 22, 2024

Editor’s Pick

  • Israel’s strike on Iran took out missile defense systems, Islamic Republic ‘is essentially naked’

    October 30, 2024
  • US must expand nuclear arsenal in face of Russia and China threat, warns top Obama defense adviser

    July 30, 2024
  • GOP Georgia Senate candidate targets vulnerable Jon Ossoff in ad depicting transgender ‘fan’

    May 27, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock